Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 56

Sort by

Sort Order Select

Journal Articles

Phase 1 Trial of Dendritic Cell/AML Fusion Cell Vaccine after Allogeneic Stem Cell Transplant in Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 772.

https://doi.org/10.1182/blood-2023-190832

Published: 2023

Journal Articles

4-1bb Enrichment Enhances Adoptive T Cell Therapy for Hematological Malignancies Using a Novel Approach for Ex Vivo Immune Cell Priming with DC/Tumor Fusion Vaccine

Kathrine S Rallis, Jessica Liegel, Giulia Cheloni, Poorva Bindal, Isabella Saldarriaga, Junyan Zhang, Georges Chedid, Joseph Abirached, John G. Clohessy, Sophia Adamia, Kai W Wucherpfennig, Donald Kufe, Jacalyn Rosenblatt, David Avigan

Blood (2023) 142 (Supplement 1): 2066.

https://doi.org/10.1182/blood-2023-182381

Published: 2023

Journal Articles

Targeting Mitochondrial Apoptotic Priming State to Personalize Therapy for Relapsed Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 48.

https://doi.org/10.1182/blood-2023-189156

Published: 2023

Journal Articles

Identification a Novel Molecular Mechanism Underlying the Anti-CD38-Based Treatment Resistance in Multiple Myeloma Patients

Sophia Adamia, Daisuke Ogiya, Evdoxia Hatjiharissi, Michael P. Chu, Zuzana Chyra, Kenneth Wen, Yu-Tzu Tai, David M. Dorfman, Teru Hideshima, Kenneth C. Anderson

Blood (2022) 140 (Supplement 1): 2081–2082.

https://doi.org/10.1182/blood-2022-169943

Published: 2022

Journal Articles

Altered Expression of Epigenetic Modifiers Identifies Novel Biomarkers and Therapeutic Targets in AL Amyloidosis

Zuzana Chyra, Morgan O'Keefe, Tereza Sevcikova, Roman Hajek, Kenneth C. Anderson, Sophia Adamia

Blood (2021) 138 (Supplement 1): 4719.

https://doi.org/10.1182/blood-2021-153532

Published: 2021

Journal Articles

B Cell Transcriptional Coactivator POU2AF1 (BOB-1) Is an Early Transcription Factor Modulating the Protein Synthesis and Ribosomal Biogenesis in Multiple Myeloma: With Therapeutic Implication

Zuzana Chyra, Mehmet K. Samur, Anil Aktas-Samur, Yao Yao, Sanika Derebail, Tommaso Perini, Yan Xu, Eugenio Morelli, Sophia Adamia, Woojun D Park, Lin Charles, Ryosuke Shirasaki, Masood A. Shammas, Constantine S. Mitsiades, Roman Hajek, Mariateresa Fulciniti, Nikhil C. Munshi

Blood (2021) 138 (Supplement 1): 2670.

https://doi.org/10.1182/blood-2021-152121

Published: 2021

Journal Articles

Identification of Novel Targets Based on Splicing Alterations for Undruggable RAS/CDK Signaling Cascade in Multiple Myeloma

Sophia Adamia, Zuzana Chyra, Morgan O'Keefe, Shruti Bhatt, Kenneth Wen, Geoffrey G Fell, Yu-Tzu Tai, Anthony G. Letai, Ivane Abiatari, David M. Dorfman, Teru Hideshima, Kenneth C. Anderson

Blood (2021) 138 (Supplement 1): 2688.

https://doi.org/10.1182/blood-2021-152986

Published: 2021

Journal Articles

The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications

Daisuke Ogiya, Jiye Liu, Hiroto Ohguchi, Keiji Kurata, Mehmet K. Samur, Yu-Tzu Tai, Sophia Adamia, Kiyoshi Ando, Teru Hideshima, Kenneth C. Anderson

Blood (2020) 136 (20): 2334–2345.

https://doi.org/10.1182/blood.2019004332

Published: 2020

Includes: Supplemental data

Journal Articles

Pre-Clinical Validation of a Novel Erk1/2 and CDK4/6 Inhibitor Combination in Multiple Myeloma (MM)

Sophia Adamia, PhD, Shruti Bhatt, PhD, Yu-Tzu Tai, PhD, Kenneth Wen, Catherine A Nicholas, Marissa S Pioso, Ivane Abiatari, MD, Anthony G. Letai, MD PhD, Kenneth Anderson, MD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-142596

Published: 2020

Journal Articles

Exploring POU2AF1 ( BOB-1 ) D ependency and Transcription Addiction in Multiple Myeloma

Zuzana Chyra, PhD, Mehmet Kemal Samur, PhD, Anil Aktas-Samur, PhD, Yan Xu, MD, Eugenio Morelli, MD, Sophia Adamia, PhD, Woojun D Park, Lin Charles, PhD, Masood A. Shammas, PhD, Roman Hajek, MD PhD, Mariateresa Fulciniti, PhD, Nikhil C. Munshi, MD

Blood (2020) 136 (Supplement 1): 49.

https://doi.org/10.1182/blood-2020-142587

Published: 2020

Journal Articles

Aberrant RHAMM Splicing in Multiple Myeloma (MM) and Its Implications for Immunotherapy

Daisuke Ogiya, MD PhD, Lisa Müller, Sigitas J Verselis, PhD, Heiner Schaal, PhD, Ivane Abiatari, MD, Ana M Stenstrom, Catherine A Nicholas, John F Daley, Michael P. Chu, David M. Dorfman, MD PhD, Linda M. Pilarski, PhD, Teru Hideshima, MD PhD, Kenneth C. Anderson, MD, Sophia Adamia, PhD

Blood (2019) 134 (Supplement_1): 1804.

https://doi.org/10.1182/blood-2019-131775

Published: 2019

Journal Articles

Altered Genomic and Epigenetic Profiling of Myeloma Bone Marrow Stromal Cells Identifies Targets for Current and Future Immunotherapeutic Approaches

Sophia Adamia, PhD, Daisuke Ogiya, MD PhD, Ivane Abiatari, MD, Sigitas J Verselis, PhD, Michael P. Chu, David M. Dorfman, MD PhD, Linda M. Pilarski, PhD, Teru Hideshima, MD PhD, Kenneth C. Anderson, MD

Blood (2019) 134 (Supplement_1): 3079.

https://doi.org/10.1182/blood-2019-131243

Published: 2019

Journal Articles

Individualized Mitochondrial Functional Approach to Combination of BCL-2 and MCL-1 Antagonism in Acute Myeloid Leukemia

Shruti Bhatt, PhD, Marissa Pioso, Elyse Ann Olesinski, Binyam Yilma, Leutz Buon, Sophia Adamia, PhD, Holly Zhu, Jeremy Ryan, Youzhen Wang, Morris Erick, Ensar Halilovic, David M. Weinstock, MD, Jacqueline S Garcia, MD, Anthony Letai

Blood (2019) 134 (Supplement_1): 2551.

https://doi.org/10.1182/blood-2019-131101

Published: 2019

Journal Articles

Cell Type-Specific Deregulation of Polypyrimidine Tract- Binding Proteins (PTBPs) Drive Aberrant Splicing in Multiple Myeloma (MM) and Acute Myeloid Leukemia (AML)

Sophia Adamia, PhD, Sigitas J Verselis, PhD, Teru Hideshima, MD PhD, Michael P. Chu, MD, Shruti Bhatt, PhD, David P. Steensma, MD, Daniel J Deangelo, Richard M. Stone, MD, Daniel G. Tenen, MD, Linda M. Pilarski, PhD, James D. Griffin, MD, Kenneth Anderson, MD

Blood (2018) 132 (Supplement 1): 3895.

https://doi.org/10.1182/blood-2018-99-118501

Published: 2018

Journal Articles

A Functional Approach to Precision Medicine Identifies Targeted Therapies for Acute Myeloid Leukemia

Shruti Bhatt, PhD, Vineeth Kumar Murali, Holly Zhu, Sophia Adamia, PhD, Amanda L Christie, BS, David M. Weinstock, MD, Jackie S Garcia, MD, Anthony Letai, MD PhD

Blood (2017) 130 (Supplement 1): 853.

https://doi.org/10.1182/blood.V130.Suppl_1.853.853

Published: 2017

Journal Articles

Identification Cause of Aberrant Splicing and Novel Drug Targets in Patients with Multiple Myeloma

Sophia Adamia, PhD, Teru Hideshima, MD PhD, Kenneth C Anderson, MD

Blood (2017) 130 (Supplement 1): 4340.

https://doi.org/10.1182/blood.V130.Suppl_1.4340.4340

Published: 2017

Journal Articles

FLT3 Splice Variant (FLT3Va) As a Potential Immunotherapeutic Target in Patients with Acute Myeloid Leukemia (AML)

Sophia Adamia, PhD, Jeffrey Nemeth, PhD, Shruti Bhatt, PhD, Sarah R Walker, Natalie I Voeks, William Lento, PhD, Ricardo M. Attar, Ilene Galinsky, MSN, ANPc, David A Frank, MD PhD, Martha Wadleigh, MD, Anthony Letai, MD PhD, David P. Steensma, MD, David M. Weinstock, MD, Daniel J. DeAngelo, MD PhD, David M. Dorfman, MD PhD, Richard M. Stone, MD, James D Griffin, MD

Blood (2016) 128 (22): 1681.

https://doi.org/10.1182/blood.V128.22.1681.1681

Published: 2016

Journal Articles

Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells

Blood (2016) 127 (9): 1138–1150.

https://doi.org/10.1182/blood-2015-06-649970

Published: 2016

Includes: Supplemental data

Journal Articles

Use of 2HG Levels in the Serum, Urine, or Bone Marrow to Predict IDH Mutations in Adults with Acute Myeloid Leukemia

Andrew M. Brunner, MD, Donna S Neuberg, ScD, Seth A. Wander, MD PhD, Hossein Sadrzadeh, MD, Karen K. Ballen, MD, Philip C. Amrein, MD, Gabriela S. Hobbs, MD, Yi-Bin Chen, MD, Ashley M. Perry, BS, Christelle Joseph, Meghan E. Burke, Aura Y Ramos, Regina Silver, Ilene Galinsky, ANP, Sophia Adamia, PhD, Darrell Borger, PhD, Anthony J Iafrate, MD PhD, Richard M. Stone, MD, Amir T. Fathi, MD

Blood (2015) 126 (23): 2597.

https://doi.org/10.1182/blood.V126.23.2597.2597

Published: 2015

Journal Articles

A Novel Synthetic Lethal Approach Targeting SIRT6 in Acute Myeloid Leukemia

Michele Cea, MD, Antonia Cagnetta, MD, Davide Lovera, MD, Raffaella Grasso, PhD, Nicoletta Colombo, PhD, Micaela Bergamaschi, MD, Sara Aquino, MD, Fabio Guolo, MD, Paola Minetto, MD, Filippo Ballerini, MD, Letizia Canepa, MD, Sophia Adamia, PhD, Alessio Nencioni, Ivana Pierri, MD, Marino Clavio, Maurizio Miglino, PhD, Marco Gobbi, MD, Roberto Massimo Lemoli, MD

Blood (2015) 126 (23): 1375.

https://doi.org/10.1182/blood.V126.23.1375.1375

Published: 2015

NARROW

Phase 1 Trial of Dendritic Cell/AML Fusion Cell Vaccine after Allogeneic Stem Cell Transplant in Acute Myeloid Leukemia

4-1bb Enrichment Enhances Adoptive T Cell Therapy for Hematological Malignancies Using a Novel Approach for Ex Vivo Immune Cell Priming with DC/Tumor Fusion Vaccine

Targeting Mitochondrial Apoptotic Priming State to Personalize Therapy for Relapsed Acute Myeloid Leukemia

Identification a Novel Molecular Mechanism Underlying the Anti-CD38-Based Treatment Resistance in Multiple Myeloma Patients

Altered Expression of Epigenetic Modifiers Identifies Novel Biomarkers and Therapeutic Targets in AL Amyloidosis

B Cell Transcriptional Coactivator POU2AF1 (BOB-1) Is an Early Transcription Factor Modulating the Protein Synthesis and Ribosomal Biogenesis in Multiple Myeloma: With Therapeutic Implication

Identification of Novel Targets Based on Splicing Alterations for Undruggable RAS/CDK Signaling Cascade in Multiple Myeloma

The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications

Pre-Clinical Validation of a Novel Erk1/2 and CDK4/6 Inhibitor Combination in Multiple Myeloma (MM)

Exploring POU2AF1 ( BOB-1 ) D ependency and Transcription Addiction in Multiple Myeloma

Aberrant RHAMM Splicing in Multiple Myeloma (MM) and Its Implications for Immunotherapy

Altered Genomic and Epigenetic Profiling of Myeloma Bone Marrow Stromal Cells Identifies Targets for Current and Future Immunotherapeutic Approaches

Individualized Mitochondrial Functional Approach to Combination of BCL-2 and MCL-1 Antagonism in Acute Myeloid Leukemia

Cell Type-Specific Deregulation of Polypyrimidine Tract- Binding Proteins (PTBPs) Drive Aberrant Splicing in Multiple Myeloma (MM) and Acute Myeloid Leukemia (AML)

A Functional Approach to Precision Medicine Identifies Targeted Therapies for Acute Myeloid Leukemia

Identification Cause of Aberrant Splicing and Novel Drug Targets in Patients with Multiple Myeloma

FLT3 Splice Variant (FLT3Va) As a Potential Immunotherapeutic Target in Patients with Acute Myeloid Leukemia (AML)

Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells

Use of 2HG Levels in the Serum, Urine, or Bone Marrow to Predict IDH Mutations in Adults with Acute Myeloid Leukemia

A Novel Synthetic Lethal Approach Targeting SIRT6 in Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only